Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas.
Wanibuchi M, Kataoka-Sasaki Y, Sasaki M, Oka S, Otsuka Y, Yamaguchi M, Ohnishi H, Ohtaki S, Noshiro S, Ookawa S, Mikami T, Mikuni N, Honmou O. Interleukin-13 receptor alpha 2 as a marker of poorer prognosis in high-grade astrocytomas. Journal Of Neurosurgical Sciences 2017, 62: 239-244. PMID: 28079349, DOI: 10.23736/s0390-5616.16.03793-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAstrocytomaBiomarkers, TumorBrain NeoplasmsChildChild, PreschoolFemaleHumansInterleukin-13 Receptor alpha2 SubunitMaleMiddle AgedNeoplasm GradingPrognosisSurvival RateYoung AdultConceptsHigh-grade astrocytomasInterleukin-13 receptor alpha 2Overall survivalMIB-1 indexReceptor alpha 2Median OSPoor prognosisPatient ageCox proportional hazards modelWorld Health Organization gradeMedian overall survivalMedian survival benefitAdvanced patient ageAlpha 2Real-time quantitative reverse transcription polymerase chain reactionLow expression groupQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionProportional hazards modelTranscription-polymerase chain reactionExpression levelsSubset of casesParaffin-embedded glioma samplesHazard ratioSurvival benefit